An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00933205|
Recruitment Status : Approved for marketing
First Posted : July 7, 2009
Last Update Posted : November 30, 2016
|Condition or disease||Intervention/treatment|
|HIV Infections||Drug: Tipranavir|
|Study Type :||Expanded Access|
|Official Title:||An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options.|
|Study Start Date :||May 2004|
|Primary Completion Date :||June 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00933205
Show 215 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim|